UPDATE: Morgan Stanley Upgrades Vertex Pharmaceuticals to Equal-Weight; Interim CF Data
Morgan Stanley raises its rating on Vertex Pharmaceuticals (NASDAQ: VRTX) from Underweight to Equal-weight and raises its price target from $28 to 51.
Morgan Stanley says, "We upgrade VRTX to EW. CF data were better than anticipated, but key data unknowns still exist. We add VX-809 sales to our base case model."
VRTX closed at $58.12 on Monday.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.